anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: The objective of this study was to investigate the role of fenofibrate, a peroxisome proliferator-activated receptor-α agonist, in obesity-induced kidney damage (lipotoxicity) in mice with uninephrectomy.
METHODS: C57BL/6 mice underwent uninephrectomy and sham surgeries and were fed normocaloric or high-fat diets. After 10 weeks, obese mice were administered 0.02% fenofibrate for 10 weeks. Kidney function and morphology were evaluated, as well as levels of inflammatory and fibrotic mediators and lipid metabolism markers.
RESULTS: High-fat diet-fed mice developed characteristic obesity and hyperlipidemia, with subsequent renal lipid accumulation and damage, including mesangial expansion, interstitial fibrosis, inflammation, and proteinuria. These changes were greater in obese uninephrectomy mice than in obese sham mice. Fenofibrate treatment prevented hyperlipidemia and glomerular lesions, lowered lipid accumulation, ameliorated renal dysfunction, and attenuated inflammation and renal fibrosis. Furthermore, fenofibrate treatment downregulated renal tissue expression of plasminogen activator inhibitor-1, monocyte chemoattractant protein-1, and local expression of fibroblast growth factor-21.
CONCLUSION: Peroxisome proliferator-activated receptor-α activation by fenofibrate, with subsequent lipolysis, attenuated glomerular and tubulointerstitial lesions induced by renal lipotoxicity, thus protecting the kidneys of uninephrectomy mice from obesity-induced lesions. The study findings suggest a pathway in the pharmacological action of fenofibrate, providing insight into the mechanisms involved in kidney damage caused by obesity in kidney donors.
The invention discloses an ointment for treating burns and scalds. The ointment comprises the following ingredients: rhubarb root and rhizome, radix arnebiae, garden burnet root, coptis root, antelope horn, giant knotweed rhizome, radix rehmanniae, panax pseudo ginseng, aloes, tea leaves, liquorice, honeysuckle, talc, dandelions, yellow wax, borneol, Chinese wolfberry root-bark, frankincense, sesame, bezoar, gypsum, liuyipowd, gypsum rubrum, myrrh and the like. The medicinal ingredients can be reasonably extracted by adopting specific classified and step extraction and decoction. The ointment obtained by the preparation method has more obvious treatment effects than ointments obtained by adopting common ointment preparation methods. For the child patients under 12, with stronger tissue regeneration capacity, the wounds of the child patients are basically repaired through cold compress for 10-15 days, cold compress is continued for about 10 days, the skins fade from red, the colors are close to the colors of the skin tissues around the wounds and colour difference hardly exists. The cure rate of the ointment disclosed by the invention is above 98%. Scars are avoided after curing.
Recent work suggests that the adult human brain is very adaptable when it comes to sensory processing. In this context, it has also been suggested that structural "blueprints" may fundamentally constrain neuroplastic change, e.g. in response to sensory deprivation. Here, we trained 12 blind participants and 14 sighted participants in echolocation over a 10-week period, and used MRI in a pre-post design to measure functional and structural brain changes. We found that blind participants and sighted participants together showed a training-induced increase in activation in left and right V1 in response to echoes, a finding difficult to reconcile with the view that sensory cortex is strictly organized by modality. Further, blind participants and sighted participants showed a training induced increase in activation in right A1 in response to sounds per se (i.e. not echo-specific), and this was accompanied by an increase in gray matter density in right A1 in blind participants and in adjacent acoustic areas in sighted participants. The similarity in functional results between sighted participants and blind participants is consistent with the idea that reorganization may be governed by similar principles in the two groups, yet our structural analyses also showed differences between the groups suggesting that a more nuanced view may be required.
Patient will start Tolvaptan in a split dose regimen 45 mg as first dose, followed by 15 mg 8 hours later. Those tolerating this dose will uptitrate to 60/30 mg and then to 90/30 mg a day. Those not tolerating 45/15 mg a day will drop out.
Risk assessment of developing preeclampsia between 11 and 14 WG based on maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentration. Patients at high risk of preeclampsia are treated with aspirin.
CBASP as the experimental intervention will follow a manual (McCullough, 2000; German version: Schramm et al., 2006). The approach is specifically tailored for the treatment of chronic forms of depression, particularly with early-onset by focusing on the problems resulting from an inhibition of maturation in early childhood and by using the therapeutic relationship in a personal, disciplined way as well as other specific techniques (e.g. Interpersonal Discrimination Exercise, Situation Analysis). CBASP integrates behavioural, cognitive, and interpersonal strategies.
Overdosage of chlordiazepoxide hydrochloride and clidinium bromide capsules, which contains a benzodiazepine (chlordiazepoxide hydrochloride) and an anticholinergic (clidinium bromide) may manifest signs and symptoms related to either of its components, although some effects such as altered levels of consciousness may be synergistic.

Overdosage of benzodiazepines, such as chlordiazepoxide hydrochloride, is characterized by central nervous system depression ranging from drowsiness to coma. In mild to moderate cases, symptoms can include drowsiness, confusion, dysarthria, lethargy, hypnotic state, diminished reflexes, ataxia, and hypotonia. Rarely, paradoxical or disinhibitory reactions (including agitation, irritability, impulsivity, violent behavior, confusion, restlessness, excitement, and talkativeness) may occur. In severe overdosage cases, patients may develop respiratory depression and coma.

Signs and symptoms of anticholinergic overdosage are related to excessive anti-muscarinic anticholinergic activity. Peripheral signs and symptoms may include dry mucous membranes and skin, flushing, tachycardia, hypertension, ileus, urinary retention, and mydriasis. Garbled speech is often pathognomonic. Central signs and symptoms may include agitation and delirium, seizures, and hyperthermia. Benzodiazepines are considered a first-line treatment for anticholinergic toxicity acting to treat mild to moderate agitation and prevent seizures.

  


Overdosage of benzodiazepines in combination with other CNS depressants (including alcohol and opioids) may be fatal (see WARNINGS, Dependence and Withdrawal Reactions). Markedly abnormal (lowered or elevated) blood pressure, heart rate, or respiratory rate raise the concern that additional drugs and/or alcohol are involved in the overdosage. Anticholinergic drugs usually increase heart rate and blood pressure. In managing benzodiazepine overdosage, employ general supportive measures, including intravenous fluids, and airway management.

Flumazenil, a specific benzodiazepine receptor antagonist is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in the management of benzodiazepine overdosage. Use of flumazenil may increase the risk of seizures in mixed overdosage with drugs that may precipitate seizures, including anticholinergic medications. Benzodiazepines are used to treat agitated delirium from anticholinergic toxicity. Therefore flumazenil administration may worsen the anticholinergic delirium and should generally be avoided.

Anticholinesterase inhibitors may reverse severe agitated delirium that is not controlled by benzodiazepines. They may also improve the airway and breathing in CNS depressed patients. Caution is warranted especially in mixed drug overdoses.

Consider contacting a poison center (1-800-222-1222) or a medical toxicologist for overdosage management recommendations.
A cosmetic composition for temporarily shaping keratinous fibres, in particular human hair, comprising a film-forming agent and a rheology modifier, wherein the film-forming agent is a homopolymer or copolymer derived from itaconic acid, having formula (I): in which the repeat unit M1 represents a vinyl monomer unit, X represents hydrogen or an alkali metal; a is from 50 to 100 mol% and b is from 0 to 50 mol%; and wherein the rheology modifier is a polysaccharide, is provided. The polymer may be a homopolymer of sodium itaconate. The polymer may comprise a repeat unit comprising a decarboxylated derivative of itaconic acid. The rheology modifier may be hydroxyethyl cellulose, hydroxypropyl cellulose, microcrystalline cellulose, xanthan gum, gum Arabic, gellan gum, carrageenan, carob bean gum, tara gum or a starch. Use of said cosmetic for temporarily shaping keratinous fibres is provided. A method for temporarily shaping keratinous fibres in provided.
The invention relates to a method for preparing medicine used for treating liver-stomach disharmony and blood stasis collateral obstruction and belongs to the field of traditional Chinese medicine. The method combines the technologies that white peony roots and liquorice roots are subjected to biological enzymolysis, rhizoma bletillae, poria cocos and corydalis tubers are decocted, panax notoginseng is extracted through alcohol, and cuttlebone is smashed. The medicine is used for treating stomach duct pain, pain in both sides of the chest, belching and acid regurgitation which are caused by liver-stomach disharmony and blood stasis collateral obstruction. The medicine is used for patients suffering from acute and chronic gastritis, gastric ulcers, duodenal ulcers and gastrorrhagia with the preceding syndromes. Texture and properties of all medicine materials in the composition are fully considered, the dissolution rate of the effective ingredients of the medicine can be increased by adopting the advanced extraction technology in a targeted mode, and product quality improvement is facilitated. Utilization of the effective ingredients of the medicine and product quality are guaranteed to the largest extent, and the treatment effect of the medicine is improved.
PURPOSE:To obtain as a synthetic intermediate for macrolides useful as antiulcer agents, antimicrobial agents, etc. CONSTITUTION:A compound expressed by formula I (R<1> is tert. butyldiphenylsilyl, tert. butyldimethylsilyl, methoxymethyl, acetyl or benzoyl). The compound is obtained by reacting a compound expressed by formula II (Me is methyl) with tert. BuPh2SiCl and imidazole used as reagents in a solvent of DMF at 0 deg.C to ambient temperature for 1-5hr. Lactol expressed by formula II is obtained by reacting a lactone expressed by formula III with a diisobutylalminamhydride reagent in a solvent such as toluene. By using this intermediate, macrolides can be stereoselectively produced in high yield and purity.
NEW MATERIAL:A compound shown by the formula I (R1 and R2 are H, or lower alkyl; A is OH, amino, its salt, O-lower alkyl). EXAMPLE:A compound shown by the formula II. USE:An agent for immunotherapy. Having no toxicity at all, quickly being absorbed and excreted in organisms, satisfying two exclusive conditions wherein effective pharmaceutical activities are manifested and continued with its constant dose. PROCESS:A cinnamic acid derivative shown by the formula II (B is ester from cyano, carboxyl, haloformyl, carbamoyl, or lower alkyl) is reacted directly or indirectly with a trihalogermane (e.g., trichlorogermane, etc.) shown by the formula X3GeH to give a trihalogermylcinnamic acid derivative shown by the formula III, which is hydrolyzed with an acid or alkali.
The insular cortex is an important hub for sensory and emotional integration. It is one of the areas consistently found activated during pain. While the insular's connections to the limbic system might play a role in the aversive and emotional component of pain, its connections to the descending pain system might be involved in pain intensity coding. Here, we used anterograde tracing with viral expression of mCherry fluorescent protein, to examine the connectivity of insular axons to different brainstem nuclei involved in the descending modulation of pain in detail. We found extensive connections to the main areas of descending pain control, namely, the periaqueductal gray (PAG) and the raphe magnus (RMg). In addition, we also identified an extensive insular connection to the parabrachial nucleus (PBN). Although not as extensive, we found a consistent axonal input from the insula to different noradrenergic nuclei, the locus coeruleus (LC), the subcoereuleus (SubCD) and the A5 nucleus. These connections emphasize a prominent relation of the insula with the descending pain modulatory system, which reveals an important role of the insula in pain processing through descending pathways.
This laboratory-based study will aim to enroll 50 current cigarillo users to complete a 20-day, randomized, parallel design protocol. After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to one of two conditions, 2 cigarillos per pack versus 4 cigarillos per pack, to examine how quantity per pack affects use patterns, including daily consumption and cigar smoking topography. Participants will be asked to attend 2 in-person sessions on Days 5 and 20. On Days 0, 9, 12 and 16 participants will complete sessions with research staff remotely (i.e. by phone or video call). Sessions will occur every 3-5 days, for a total of 6 sessions across 20 days.
STUDY DESIGN: Retrospective clinical study.
OBJECTIVES: We aimed to investigate preoperative spinopelvic mismatch as a risk factor for recurrent lumbar disk herniation (RLDH) in patients undergoing lumbar disk herniation (LDH) surgery.
SUMMARY OF BACKGROUND DATA: Spinopelvic parameters have been associated with lumbar degenerative diseases, particularly LDH. However, the relationship between these parameters and RLDH has yet to be studied.
MATERIALS AND METHODS: Data of 1453 patients aged ≥18 who underwent single-level, unilateral fenestration microdiscectomy for the first time in our hospital between 2013 and 2019 were reviewed. The study group comprised 88 patients who underwent surgery for RLDH. The control group comprised 101 randomly selected patients who underwent surgery for LDH but not RLDH. Age, sex, body mass index, occupational activity level, operative level, Roussouly classification type, and time to recurrence were recorded. Moreover, pelvic incidence, lumbar lordosis (LL), interverteberal disk height (IDH), segmental lordosis, sacral slope (SS), pelvic tilt (PT), and sacral table angle (ST) were measured for each patient. Pelvic mismatch was calculated.
RESULTS: Mean age was 46.5±11.4 y (range, 20-70). Both groups were similar concerning age, sex, body mass index, occupational activity level, and level of surgery. The mean time to recurrence was 167.3±36.6 d (range, 62-363). Measurements in the RLDH group were as follows: IDH=7.6±1.5 mm, pelvic incidence =54.4°±10.1°, LL=47.3°±13°, segmental lordosis =9.3°±5°, SS=35.1°±9.9°, and PT=19.3°±7.3°. Mean IDH was significantly lower in the RLDH group ( P =0.02). Less LL and lower PT at L3-4 level and increased SS at L5-S1 level were considered risk factors for RLDH.
CONCLUSION: This study showed that preoperative low IDH is at higher risk for RLDH in patients undergoing LDH surgery. LL, PT, and SS may be risk factors for specific levels.
BACKGROUND/AIM: Endoscopic submucosal dissection (ESD) followed by chemoradiotherapy (CRT) has become a promising treatment modality in the management of early-stage superficial esophageal squamous cell carcinoma (SESCC). However, radiotherapy often leads to significant adverse events (AEs), including cardiopulmonary toxicity, limiting the delivery of this treatment modality. This study aimed to evaluate the efficacy of reduced-volume radiotherapy and dose-dense chemotherapy in mitigating AEs for high-risk SESCC following ESD.
PATIENTS AND METHODS: We retrospectively analyzed patients treated with customized CRT after ESD between 2014 and 2023.
RESULTS: Thirty-nine consecutive patients were identified. The median follow-up period was 63.4 months (range=8.3-99.8 months). All patients completed CRT, with a low incidence (3%) of grade ≥3 nonhematologic AEs. Thirteen patients (33%) had a recurrence: 10 local, one regional, and two distant. The 5-year overall and disease-free survival rates were 77% and 64%, respectively. A positive vertical resection margin was identified as a prognostic factor associated with survival.
CONCLUSION: Our novel approach of combining ESD with customized reduced-volume radiotherapy and dose-dense chemotherapy shows promise in providing favorable oncologic outcomes and a safer nonsurgical strategy for high-risk SESCC. Specifically, this regimen minimized cardiopulmonary toxicity without compromising therapeutic efficacy. More aggressive adjuvant therapy may be required for patients with positive vertical resection margins after ESD.
Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
FIELD: biotechnology.SUBSTANCE: described is a poxvirus-based expression vector which contains a nucleic acid molecule(s) coding a hybrid of heteroligomer mycobacterial antigens ESAT6 and CFP10 and preferably a hybrid comprising the amino acid sequence presented in SEQ ID NO: 1. Disclosed is a host cell for producing a poxvirus-based vector according to any of the claims. 1–13, comprising a poxvirus-based vector according to any of claims. 1–13. Described is a composition for treating or preventing a mycobacterial infection or any disease and pathological condition caused or associated with such a mycobacterial infection, containing an effective amount of a vector according to any of the claims. 1–13 or a host cell according to claim 14 or any combination thereof.EFFECT: present invention serves to induce or stimulate an immune response in order to provide a protective response against a mycobacterial infection or any disease caused or associated with a mycobacterial infection.26 cl, 2 dwg, 4 tbl, 4 ex
PURPOSE: To improve moisture resistance and condensing magnification by mixing an edible water-soluble polysaccharides with a solid form preparation of a condensed Chinese medicine extract. CONSTITUTION: This moisture proof preparation of Chinese medicine comprises 100 pts.wt. solid form preparation of a Chinese medicine extract, 50-200 pts.wt. cone starch and 1-200 pts.wt. water-soluble polysaccharides. The preparation can not only dissolve the problem of the condensed Chinese medicine extract of easily cohering by absorbing moisture but also improve condensing magnification of the Chinese medicine which is a traditional medicine by using an edible, highly safe and water-soluble polysaccharides.
Study subjects will be drawn from patients who are at-risk for cardiac disease and who have been referred for 2D transthoracic echocardiogram as standard of care. All will receive a MyoVista wavECG test.
The primary aim of the study is to evaluate the efficacy of nifedipine gastrointestinal therapeutic system (GITS) on lowering blood pressure in Chinese adults with mild-to-moderate hypertension. The secondary aim of the study is to evaluate the efficacy of Nifedipine GITS on lowering blood pressure in hypertensive patients with different urinary sodium levels. Based on sample size estimation, the plan is to recruit 700 patients from 16 centers. At baseline, patients'demographic characters, disease history and anthropometric indices will be collected, laboratory tests will be performed for blood routine examination, urinalysis, renal function, hepatic function, urinary sodium and 24-hour urinary sodium. All eligible patients will be assigned to a treatment of Nifedipine GITS and followed up for 8 weeks. At 0 day, 2,weeks, 4 weeks and 8 weeks of the study, seated blood pressure, vital signs, medication and adverse events were collected. At the end of the study, 24-hour ambulatory blood pressure monitoring (ABPM) will be performed for all participants.
The smartphone jaundice app system works by taking pictures of newborns with a custom-made color calibration card placed on their chest. This makes it possible to measure the skin color precisely regardless of the specific light source that is used to illuminate the newborn. The measured skin color is then compared with items in a database of simulated newborn skin colors. These simulated newborn skin colors have been created using numerical simulations of how light moves through skin, with varying skin parameters including, but not limited to, skin thickness, blood concentration, melanin, and of course bilirubin, the pigment that causes jaundice. By comparing the measured skin color with the simulated skin colors that are most similar to it, the investigators can then estimate the bilirubin concentration in the newborn's skin by e.g. averaging the bilirubin concentrations used to create these simulated skin colors.

In a group of 200 newborns with varying degree of jaundice, correlation between smartphone bilirubin estimates will be compared with total serum bilirubin and standard transcutaneous bilirubinometry.
The physical activity intervention is based on national guidelines of physical activity in cancer rehabilitation. A physiotherapist together with each patient will develop individual adaptations to the exercise protocol, with suggestions on which type of exercise the participant is able to perform depending on their daily condition. Suggestions on physical activity for good, bad and in-between-days will be listed in collaboration with the participant, and the participant will report number of minutes/day in each of the 3 physical activity levels stated.
The invention provides application of antibacterial peptide NZX in preparation of a streptococcus agalactiae antibacterial drug. The invention discovers that the antibacterial peptide NZX has an inhibiting effect on streptococcus agalactiae for the first time. Experiments show that NZX has high-efficiency, rapid sterilization and low drug resistance effects on streptococcus agalactiae. The antibacterial activity and the sterilization rate of the antibacterial peptide NZX on the streptococcus agalactiae are obviously better than those of the florfenicol, the hemolysis rate is lower, and the stability of blood plasma and blood serum is higher. NZX acts by killing bacteria by inhibiting bacterial cell wall synthesis; the inhibition rate of the initial biofilm at the concentration of 64 multiplied by MIC is 49.0 percent; the haemolysis rate at 256 × MIC is only 0.71%; NZX retained 97.8% and 98.9% activity, respectively, after 60min of incubation with 25% serum and plasma. NZX is expected to be developed as a novel agent for the treatment of streptococcal diseases caused by Streptococcus agalactiae.